Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors

• Published in: Frontiers in cellular and infection microbiology Vol. 15; p. 1598193
• Main Authors: Xu, Shaowei, Pang, Qingqing, Wei, Meng, Liu, Danxi, Yuan, Du, Bai, Tao, Wang, Xiaobo, Tang, Zhihong, Wu, Feixiang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2025
• Subjects: Adult; Aged; Antiviral Agents - therapeutic use; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - surgery; Carcinoma, Hepatocellular - therapy; Carcinoma, Hepatocellular - virology; Cellular and Infection Microbiology; Chemoembolization, Therapeutic; conversion therapy; DNA, Viral; Female; HBV reactivation; Hepatitis B - complications; Hepatitis B - drug therapy; Hepatitis B - virology; Hepatitis B virus - drug effects; Hepatitis B virus - physiology; hepatocellular carcinoma; Humans; Immune Checkpoint Inhibitors - therapeutic use; Liver Neoplasms - drug therapy; Liver Neoplasms - mortality; Liver Neoplasms - surgery; Liver Neoplasms - therapy; Liver Neoplasms - virology; Male; Middle Aged; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies; Risk Factors; surgery; survival; Tyrosine Kinase Inhibitors; Virus Activation - drug effects; conversion therapy; HBV reactivation; hepatocellular carcinoma; survival; surgery

This study aimed to investigate hepatitis B virus (HBV) reactivation and its impact on postoperative survival in patients with HBV-related hepatocellular carcinoma (HCC) who underwent conversion therapy. The therapeutic regimen consisted of interventional procedures (hepatic artery infusion chemothe...